Parkinson's disease (PD) is a ubiquitous brain cell degeneration disease and presents a significant therapeutic challenge. By injecting 6-hydroxydopamine (6-OHDA) into the left medial forebrain bundle, rats were made to exhibit PD-like symptoms and treated by intranasal administration of a low-dose (2 × 10 5 ) or high-dose (1 × 10 6 ) human neural stem cells (hNSCs). Apomorphine-induced rotation test, stepping test, and open field test were implemented to evaluate the motor behavior and high-performance liquid chromatography was carried out to detect dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), serotonin, and 5-hydroxyindole-3-acetic acid in the striatum of rats. Animals injected with 6-OHDA showed significant motor function deficits and damaged dopaminergic system compared to the control group, which can be restored by hNSCs treatment. Treatment with hNSCs significantly increased the tyrosine hydroxylase-immunoreactive cell count in the substantia nigra of PD animals. Moreover, the levels of neurotransmitters exhibited a significant decline in the striatum tissue of animals injected with 6-OHDA when compared to that of the control group. However, transplantation of hNSCs significantly elevated the concentration of DA and DOPAC in the injured side of the striatum. Our study offered experimental evidence to support prospects of hNSCs for clinical application as a cell-based therapy for PD.
Keyphrases
- cell therapy
- low dose
- high dose
- stem cells
- single cell
- high performance liquid chromatography
- endothelial cells
- multiple sclerosis
- traumatic brain injury
- induced pluripotent stem cells
- prefrontal cortex
- minimally invasive
- mass spectrometry
- metabolic syndrome
- subarachnoid hemorrhage
- drug induced
- mesenchymal stem cells
- high resolution
- brain injury
- uric acid
- combination therapy
- smoking cessation
- liquid chromatography